Amylin Pharmaceuticals, Inc. and Illumina, Inc. Benefit From JOBS Act
March 30 2012 - 8:20AM
Marketwired
The Biotechnology Industry's future looks very promising with the
passing of the Jumpstart Our Business Startups (JOBS) Act. The JOBS
Act, which passed in the Senate by a vote of 73-26, contains
several provisions which would make the pathway to capital
formation more attainable for small biotechnology companies,
clearing the way for American innovation and ingenuity by removing
bureaucratic hurdles and red tape to speed cures and medical
breakthroughs to patients. The Paragon Report examines the outlook
for companies in the Biotechnology Industry and provides equity
research on Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) and
Illumina, Inc. (NASDAQ: ILMN).
Access to the full company reports can be found at:
www.paragonreport.com/AMLN www.paragonreport.com/ILMN
The Biotechnology Industry Organization (BIO) President and CEO
Jim Greenwood recently made the following statement: "BIO applauds
passage of the JOBS Act and all efforts to incentivize and
encourage capital formation for growing companies. This legislation
would make capital formation easier for small, emerging
biotechnology companies, speeding the development of new cures and
treatments for patients living with debilitating diseases such as
cancer, diabetes, Parkinson's, and HIV/AIDS. Bringing such
groundbreaking cures and treatments from bench to bedside is a long
and arduous road, and biotechnology companies are at the forefront
of the effort."
"These reforms are especially important to innovative
biotechnology companies that do not yet have product revenue and
must spend investor dollars on compliance rather than the search
for cures and breakthrough medicines," Greenwood explained.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the Biotechnology Industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Amylin Pharmaceuticals, Inc. shares rose as much as 51 percent
on Wednesday after Bloomberg News reported the company rejected a
$3.5 billion unsolicited takeover bid from Bristol-Myers Squibb
Co.
Illumina, Inc. announced that it has recommended that its
stockholders take no action at this time in response to Roche's
announcement that it is now offering to acquire Illumina for $51.00
per share in cash. Consistent with its fiduciary duties and
responsibilities, and in consultation with its financial and legal
advisors, Illumina's Board of Directors will thoroughly review
Roche's revised proposal and make a recommendation to stockholders
regarding the proposal in due course.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Aug 2023 to Aug 2024